277 related articles for article (PubMed ID: 25869616)
1. 11β-HSD1 reduces metabolic efficacy and adiponectin synthesis in hypertrophic adipocytes.
Koh EH; Kim AR; Kim H; Kim JH; Park HS; Ko MS; Kim MO; Kim HJ; Kim BJ; Yoo HJ; Kim SJ; Oh JS; Woo CY; Jang JE; Leem J; Cho MH; Lee KU
J Endocrinol; 2015 Jun; 225(3):147-58. PubMed ID: 25869616
[TBL] [Abstract][Full Text] [Related]
2. Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes.
Nakano S; Inada Y; Masuzaki H; Tanaka T; Yasue S; Ishii T; Arai N; Ebihara K; Hosoda K; Maruyama K; Yamazaki Y; Shibata N; Nakao K
Am J Physiol Endocrinol Metab; 2007 Apr; 292(4):E1213-22. PubMed ID: 17190905
[TBL] [Abstract][Full Text] [Related]
3. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor in the diet-induced obese mice.
Park JS; Rhee SD; Jung WH; Kang NS; Kim HY; Kang SK; Ahn JH; Kim KY
Eur J Pharmacol; 2012 Sep; 691(1-3):19-27. PubMed ID: 22760069
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of 11β-hydroxysteroid dehydrogenase 1 by carbenoxolone affects glucose homeostasis and obesity in db/db mice.
Dhanesha N; Joharapurkar A; Shah G; Kshirsagar S; Dhote V; Sharma A; Jain M
Clin Exp Pharmacol Physiol; 2012 Jan; 39(1):69-77. PubMed ID: 22060140
[TBL] [Abstract][Full Text] [Related]
5. Anti-diabetic and anti-inflammatory effect of a novel selective 11β-HSD1 inhibitor in the diet-induced obese mice.
Park SB; Jung WH; Kang NS; Park JS; Bae GH; Kim HY; Rhee SD; Kang SK; Ahn JH; Jeong HG; Kim KY
Eur J Pharmacol; 2013 Dec; 721(1-3):70-9. PubMed ID: 24135201
[TBL] [Abstract][Full Text] [Related]
6. Depot-specific modulation of rat intraabdominal adipose tissue lipid metabolism by pharmacological inhibition of 11beta-hydroxysteroid dehydrogenase type 1.
Berthiaume M; Laplante M; Festuccia W; Gélinas Y; Poulin S; Lalonde J; Joanisse DR; Thieringer R; Deshaies Y
Endocrinology; 2007 May; 148(5):2391-7. PubMed ID: 17272400
[TBL] [Abstract][Full Text] [Related]
7. A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, UI-1499.
Byun SY; Shin YJ; Nam KY; Hong SP; Ahn SK
Life Sci; 2015 Jan; 120():1-7. PubMed ID: 25447448
[TBL] [Abstract][Full Text] [Related]
8. Adipose tissue-targeted 11β-hydroxysteroid dehydrogenase type 1 inhibitor protects against diet-induced obesity.
Liu J; Wang L; Zhang A; Di W; Zhang X; Wu L; Yu J; Zha J; Lv S; Cheng P; Hu M; Li Y; Qi H; Ding G; Zhong Y
Endocr J; 2011; 58(3):199-209. PubMed ID: 21325744
[TBL] [Abstract][Full Text] [Related]
9. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone (KR-66344).
Park JS; Rhee SD; Kang NS; Jung WH; Kim HY; Kim JH; Kang SK; Cheon HG; Ahn JH; Kim KY
Biochem Pharmacol; 2011 Apr; 81(8):1028-35. PubMed ID: 21315688
[TBL] [Abstract][Full Text] [Related]
10. Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects.
Alberti L; Girola A; Gilardini L; Conti A; Cattaldo S; Micheletto G; Invitti C
Int J Obes (Lond); 2007 Dec; 31(12):1826-31. PubMed ID: 17593901
[TBL] [Abstract][Full Text] [Related]
11. Resveratrol inhibits 11β-hydroxysteroid dehydrogenase type 1 activity in rat adipose microsomes.
Tagawa N; Kubota S; Kato I; Kobayashi Y
J Endocrinol; 2013 Sep; 218(3):311-20. PubMed ID: 23814014
[TBL] [Abstract][Full Text] [Related]
12. Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue.
Apostolova G; Schweizer RA; Balazs Z; Kostadinova RM; Odermatt A
Am J Physiol Endocrinol Metab; 2005 May; 288(5):E957-64. PubMed ID: 15613680
[TBL] [Abstract][Full Text] [Related]
13. Emodin, an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, regulates adipocyte function in vitro and exerts anti-diabetic effect in ob/ob mice.
Wang YJ; Huang SL; Feng Y; Ning MM; Leng Y
Acta Pharmacol Sin; 2012 Sep; 33(9):1195-203. PubMed ID: 22922341
[TBL] [Abstract][Full Text] [Related]
14. HIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models.
Okazaki S; Takahashi T; Iwamura T; Nakaki J; Sekiya Y; Yagi M; Kumagai H; Sato M; Sakami S; Nitta A; Kawai K; Kainoh M
J Pharmacol Exp Ther; 2014 Oct; 351(1):181-9. PubMed ID: 25100752
[TBL] [Abstract][Full Text] [Related]
15. 7-oxysterols modulate glucocorticoid activity in adipocytes through competition for 11beta-hydroxysteroid dehydrogenase type.
Wamil M; Andrew R; Chapman KE; Street J; Morton NM; Seckl JR
Endocrinology; 2008 Dec; 149(12):5909-18. PubMed ID: 18755798
[TBL] [Abstract][Full Text] [Related]
16. A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, INU-101.
Hong SP; Han D; Chang KH; Ahn SK
Eur J Pharmacol; 2018 Sep; 835():169-178. PubMed ID: 30096297
[TBL] [Abstract][Full Text] [Related]
17. Weight loss after gastric bypass surgery in women is followed by a metabolically favorable decrease in 11beta-hydroxysteroid dehydrogenase 1 expression in subcutaneous adipose tissue.
Simonyte K; Olsson T; Näslund I; Angelhed JE; Lönn L; Mattsson C; Rask E
J Clin Endocrinol Metab; 2010 Jul; 95(7):3527-31. PubMed ID: 20410231
[TBL] [Abstract][Full Text] [Related]
18. The 11β-hydroxysteroid dehydrogenase type 1 inhibitor protects against the insulin resistance and hepatic steatosis in db/db mice.
Yuan X; Li H; Bai H; Zhao X; Zhang C; Liu H; Zhang Y; Zhao B; Wu Y; Liu J; Xiang Q; Feng B; Chu Y; Huang Y
Eur J Pharmacol; 2016 Oct; 788():140-151. PubMed ID: 27242185
[TBL] [Abstract][Full Text] [Related]
19. A novel 11β-HSD1 inhibitor improves diabesity and osteoblast differentiation.
Park JS; Bae SJ; Choi SW; Son YH; Park SB; Rhee SD; Kim HY; Jung WH; Kang SK; Ahn JH; Kim SH; Kim KY
J Mol Endocrinol; 2014 Apr; 52(2):191-202. PubMed ID: 24444497
[TBL] [Abstract][Full Text] [Related]
20. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP
Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
